Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3040
- Registration Number
- NCT00002651
- Locations
- 🇨🇦
Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada
🇨🇦McGill Cancer Centre at McGill University, Montreal, Quebec, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-09-02
- Target Recruit Count
- 819
- Registration Number
- NCT00021450
- Locations
- 🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
🇮🇪Saint Luke's Hospital, Dublin, Ireland
🇨🇾Bank Of Cyprus Oncology Centre, Nicosia, Cyprus
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
- Conditions
- MelanomaNeoplasm Metastasis
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 141
- Registration Number
- NCT00001705
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- First Posted Date
- 2002-04-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GMP Endotherapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT00034255
- Locations
- 🇺🇸
MedStar Research Institute - Clinical Research Center, Washington, District of Columbia, United States
🇺🇸Texas Diabetes Institute, San Antonio, Texas, United States
🇺🇸VASDHS Medical Center, San Diego, California, United States
Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
- Conditions
- HIV InfectionsPeripheral Nervous System Disease
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Advanced Peptides
- Registration Number
- NCT00002083
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States
The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Columbia Research Laboratories
- Target Recruit Count
- 20
- Registration Number
- NCT00002363
- Locations
- 🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2000-02-21
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT00004635
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Wayne State University Hutzel Hospital, Detroit, Michigan, United States
🇺🇸University of Washington, Seattle, Washington, United States
dnaJ Peptide for Relieving Rheumatoid Arthritis
- First Posted Date
- 2000-01-24
- Last Posted Date
- 2007-07-31
- Lead Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Target Recruit Count
- 160
- Registration Number
- NCT00000435
- Locations
- 🇺🇸
Guthrie Clinic, Sayre, Pennsylvania, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Virginia Mason Research Center, Seattle, Washington, United States
A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).
- Conditions
- Cognition DisordersHIV Infections
- First Posted Date
- 2000-01-18
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 6
- Registration Number
- NCT00000393
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
- Conditions
- Cognition DisordersHIV Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2000-01-18
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 215
- Registration Number
- NCT00000392
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.